{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:06:05Z","timestamp":1794027965869,"version":"4.8.0"},"reference-count":22,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T00:00:00Z","timestamp":1692835200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI20\/00592"],"award-info":[{"award-number":["PI20\/00592"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FI21\/00007"],"award-info":[{"award-number":["FI21\/00007"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Regional Development Fund (ERDF)","award":["PI20\/00592"],"award-info":[{"award-number":["PI20\/00592"]}]},{"name":"European Regional Development Fund (ERDF)","award":["FI21\/00007"],"award-info":[{"award-number":["FI21\/00007"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Herein, we present the first described hereditary hemorrhagic telangiectasia (HHT) patient treated with aflibercept for severe GI involvement after tachyphylaxis to bevacizumab, with promising results. HHT is a rare genetic disease characterized by systemic vascular malformations. Gastrointestinal telangiectasia is one of the major involvements that can produce chronic severe iron-deficiency anemia. Nowadays, support treatment with iron replacement therapy, red blood cell transfusions, and antiangiogenic drugs\u2014mainly bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF)\u2014are the main therapeutic options for this complication. The evidence of alternative drugs in patients with failure to this approach, such as tachyphylaxis to bevacizumab, is scarce. Aflibercept is a VEGF inhibitor with antiangiogenic properties approved for the treatment of different types of cancer and ocular neovascularization diseases.<\/jats:p>","DOI":"10.3390\/medicina59091533","type":"journal-article","created":{"date-parts":[[2023,8,24]],"date-time":"2023-08-24T10:06:48Z","timestamp":1692871608000},"page":"1533","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Aflibercept for Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia: A Case Report"],"prefix":"10.3390","volume":"59","author":[{"given":"Bernat","family":"Villanueva","sequence":"first","affiliation":[{"name":"HHT Unit, Internal Medicine Department, Hospital Universitari de Bellvitge, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Iriarte","sequence":"additional","affiliation":[{"name":"HHT Unit, Internal Medicine Department, Hospital Universitari de Bellvitge, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Torres-Iglesias","sequence":"additional","affiliation":[{"name":"HHT Unit, Internal Medicine Department, Hospital Universitari de Bellvitge, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0271-1767","authenticated-orcid":false,"given":"Miriam","family":"Mu\u00f1oz Bola\u00f1o","sequence":"additional","affiliation":[{"name":"Pharmacist Department, Hospital Universitari Bellvitge, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4368-6260","authenticated-orcid":false,"given":"Pau","family":"Cerd\u00e0","sequence":"additional","affiliation":[{"name":"HHT Unit, Internal Medicine Department, Hospital Universitari de Bellvitge, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9411-804X","authenticated-orcid":false,"given":"Antoni","family":"Riera-Mestre","sequence":"additional","affiliation":[{"name":"HHT Unit, Internal Medicine Department, Hospital Universitari de Bellvitge, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"},{"name":"Bellvitge Biomedical Research Institute (IDIBELL), L\u2019Hospitalet de Llobregat, 08908 Barcelona, Spain"},{"name":"Faculty of Medicine and Health Sciences, Universitat de Barcelona, L\u2019Hospitalet de Llobregat, 08907 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,24]]},"reference":[{"key":"ref_1","unstructured":"(2020, July 04). The Portal for Rare Diseases and Orphan Drugs. Available online: https:\/\/www.orpha.net\/consor\/cgi-bin\/index.php."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"989","DOI":"10.7326\/M20-1443","article-title":"Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia","volume":"173","author":"Faughnan","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P","article-title":"Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome)","volume":"91","author":"Hovlin","year":"2000","journal-title":"Am. J. Med. Genet."},{"key":"ref_4","first-page":"1","article-title":"Hereditary hemorrhagic telangiectasia: Genetics and molecular diagnostics in a new era","volume":"5","author":"McDonald","year":"2015","journal-title":"Front. Genet."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13023-020-01422-8","article-title":"Current HHT genetic overview in Spain and its phenotypic correlation: Data from RiHHTa registry","volume":"15","author":"Iriarte","year":"2020","journal-title":"Orpahnet J. Rare Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.3389\/fgene.2014.00456","article-title":"Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia","volume":"5","author":"Tillet","year":"2015","journal-title":"Front. Genet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13023-019-1281-4","article-title":"Future treatments for hereditary hemorrhagic telangiectasia","volume":"15","author":"Robert","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0042-1743467","article-title":"Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: A practical evidence-based guide for clinicians","volume":"48","year":"2022","journal-title":"Semin. Thromb. Hemost."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mora-Luj\u00e1n, J.M., Iriarte, A., Alba, E., S\u00e1nchez-Corral, M., Berrozpe, A., Cerd\u00e0, P., Cruellas, F., Ribas, J., Castellote, J., and Riera-Mestre, A. (2019). Gastrointestinal Bleeding in Patients with Hereditary Hemorrhagic Telangiectasia: Risk Factors and Endoscopic Findings. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010082"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1007\/s11136-004-7865-y","article-title":"Health-related quality of life in a rare disease: Hereditary hemorrhagic telangiectasia (HHT) or Rendu-Osler-Weber disease","volume":"13","author":"Pasculli","year":"2004","journal-title":"Qual. Life Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2017.11.013","article-title":"Intravenous bevacizumab for refractory hereditary hemorrhagic telangiectasia-related epistaxis and gastrointestinal bleeding","volume":"93","author":"Iyer","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/joim.12832","article-title":"Systemic bevacizumab for the treatment of chronic bleeding in hereditary haemorrhagic telangiectasia","volume":"285","author":"Kritharis","year":"2019","journal-title":"J. Intern. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s10456-018-9646-1","article-title":"Pazopanib may reduce bleeding in hereditary hemorrhagic telangiectasia","volume":"22","author":"Faughnan","year":"2019","journal-title":"Angiogenesis"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1146080","DOI":"10.3389\/fmed.2023.1146080","article-title":"Long-term use of somatostatin analogs for chronic gastrointestinal bleeding in hereditary hemorrhagic telangiectasia","volume":"10","author":"Iriarte","year":"2023","journal-title":"Front. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1136\/gut.2003.029710","article-title":"Thalidomide for the treatment of severe intestinal bleeding","volume":"53","author":"Bauditz","year":"2004","journal-title":"Gut."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nm.2131","article-title":"Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia","volume":"16","author":"Lebrin","year":"2010","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: Explanation and elaboration document","volume":"89","author":"Riley","year":"2017","journal-title":"J. Clin. Epidemiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance Mechanisms to Anti-angiogenic Therapies in Cancer","volume":"10","author":"Haibe","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_19","first-page":"1857","article-title":"Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: A comprehensive review","volume":"10","author":"Yang","year":"2016","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"672","DOI":"10.36290\/vnl.2017.131","article-title":"P\u0159\u00ednos nov\u00fdch inhibitor\u016f angiogeneze (bevacizumab a aflibercept) pro l\u00e9\u010dbu mnoho\u010detn\u00e9 angiomat\u00f3zy: Kazuistika [The benefit of new angiogenesis (bevacizumab and aflibercept) inhibitors for multiple angiomatosis therapy: A case report]","volume":"63","author":"Adam","year":"2017","journal-title":"Vnitr. Lek."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s10456-021-09807-4","article-title":"Pazopanib for severe bleeding and transfusion-dependent anemia in hereditary hemorrhagic telangiectasia","volume":"25","author":"Parambil","year":"2022","journal-title":"Angiogenesis"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Villanueva, B., Cerd\u00e0, P., Torres-Iglesias, R., Rocamora, J., Figueras, A., Vi\u00f1als, F., and Riera-Mestre, A. (2023). Potential angiogenic biomarkers in hereditary hemorrhagic telangiectasia and other vascular diseases. Eur. J. Intern. Med.","DOI":"10.1016\/j.ejim.2023.05.020"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/9\/1533\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:38:31Z","timestamp":1760128711000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/59\/9\/1533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,24]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["medicina59091533"],"URL":"https:\/\/doi.org\/10.3390\/medicina59091533","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,24]]}}}